加州太平洋生物科学公司 PACB 深 沪
等待开盘 12-16 09:30:00 美东时间
2.11
-0.010
-0.47%
华盛通- 最 高2.17
- 今 开2.15
- 成交量 205.01万股
- 最 低 2.0613
- 昨 收 2.12
- 总市值 6.33亿
- 52周最高 2.725
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 0.8511
- 委 比 2.86%
- 总股本 3.00亿
- 历史最高 53.69
- 量 比 0.55
- 振 幅 5.13%
- 历史最低 0.8511
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
11-24 21:08
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.
11-10 22:16
Pacific Biosciences Q3 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $38.441M Miss $40.210M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 22.58 percent. This is a 29.41 percent increase over losses of $(0.17) per share
11-06 05:19
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
11-01 01:06
Cathie Wood Just Dumped $7.4 Million Worth Of Palantir And AMD Shares — Here's What Ark Is Buying Instead
Ark Invest made significant trades involving PLTR, AMD, PACB, and DASH. They sold Palantir and bought AMD, Pacific Biosciences, DoorDash, Iridium, Intellia, Deere, and Synopsys.
10-31 09:26
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE Biotechnology Holdings, Inc. announced its Q4 2025 priorities, including advancing its lead compound LB-100, pursuing acquisitions of complementary oncology assets, and enhancing operational readiness. The company is in advanced negotiations for potential transactions aligned with its strategic goals.
10-16 12:00
PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities
PacBio announced advancements in its sequencing platforms, introducing the new SPRQ-Nx chemistry to significantly lower genome sequencing costs to under $300. This innovation aims to enhance accessibility for population genomics, clinical research, and production-scale environments by reducing operational waste and offering multiomic capabilities, including 5hmC detection for epigenetic studies and 21 CFR Part 11 compliance. These updates reflect...
10-14 10:05
